Increasing evidence indicates that congenital long QT syndromes (LQTSs) promote atrial fibrillation. The atrial action potential (AP) has a short plateau, and whether LQTS atrial cardiomyocytes generate triggered activity via early afterdepolarizations (EADs) is unclear. Atrial cellular arrhythmia mechanisms have not been defined in congenital LQTS. Therefore, we studied atrial cardiomyocyte electrophysiology in mice with an LQTS3 SCN5A inactivation-impairing mutation (DKPQ heterozygotes).
Introduction
Atrial fibrillation (AF) is the most frequent sustained arrhythmia observed in clinical practice and the underlying mechanisms are incompletely understood. 1 Genetic factors are increasingly recognized to be significant contributors. Patients with long QT syndrome (LQTS) often present with atrial arrhythmias, particularly AF. 2 -4 At the ventricular level, early afterdepolarizations (EADs) induce torsade de pointes tachyarrhythmias, with underlying mechanisms having been demonstrated in murine models. 5, 6 Atrial cardiomyocytes have much shorter plateaus and slower phase 3 repolarization than ventricular cells, and their ability to generate EADs and EAD-related triggered activity is less clear. Several recent studies have examined atrial arrhythmia predisposition in mouse models of congenital LQTS. Dautova et al. 7 showed that Langendorff-perfused hearts from mice heterozygous for the DKPQ knock-in LQT3 mutation are resistant to atrial arrhythmia induction by programmed electrical stimulation, while older LQT3 mice may have a higher chance than wild-type (WT) mice of developing atrial arrhythmias. 8 We recently reported that protocols generating rapid rate alterations induce atrial arrhythmias significantly more often in DKPQ vs. WT mice in vivo, 9 suggestive of afterdepolarizationdependent arrhythmogenic mechanisms in this model, similar to prior observations at the ventricular level. 5, 6 None of these studies examined the atrial cellular phenotype of DKPQ mice. Furthermore, the range of heart rates that could be assessed was limited by the very rapid intrinsic sinus node rate of the mouse. We designed the present study to evaluate the cellular electrophysiological properties of DKPQ mice, with particular emphasis on: (i) action potential (AP) changes, including susceptibility to EADs; (ii) changes in Na + -current (I Na ) properties; and (iii) effects of the late I Na (I NaL ) blocker ranolazine on I Na and AP properties.
Methods

Animal model
Experiments were performed on age-matched pairs of adult (21-52 week) male LQTS3 mice with a heterozygous DKPQ-SCN5A knock-in mutation on a Swiss Agouti background and WT littermates as described previously. 5 The genotypes of each animal were not revealed to investigators during the performance of experiments, and analyses of experimental data were performed blinded to the genotype (DKPQ-SCN5A or WT); genotypes were revealed for statistical analysis and data presentation. Animal care procedures followed National Institutes of Health guidelines (http://oacu.od.nih.gov/training/index.htm) and were approved by the Animal Research Ethics Committee of the Montreal Heart Institute. Mice were heparinized (100 IU ip) and euthanized by cervical dislocation under 2.5% isoflurane anaesthesia. Left atrial (LA) tissue was then removed for standard microelectrode study or cell isolation and patch clamp. with a fast perfusion system that replaced cell superfusate within 500 ms. Peak I Na (I NaP ) and I NaL were defined based on 30 mM tetrodotoxin (TTX)-sensitive currents (Tocris-Bioscience, Ellisville, MO, USA). TTX-sensitive current values before and after ranolazine (Sigma) superfusion were obtained with the protocol shown in Supplementary material online, Figure S1 , to establish I Na inhibition by ranolazine in a precise fashion. The criteria for satisfactory voltage control for I NaP recordings were: (i) smooth I -V curve, without abrupt jumps on the negative-slope branch; (ii) maximum current observed around 30 mV positive to the voltage threshold (Supplementary material online, Figure S2 ).
Cell isolation
Data analysis
Clampfit 9.0 (Axon), Matlab 7.10 (R2010a), Excel 2003 (Microsoft), and GraphPad Prism 5.01 were used for data analysis. Student's t-tests were used for comparisons with two groups only and two-way ANOVA with Bonferroni-adjusted t-test was used to compare repeated measures. The occurrence rates of EADs were compared between groups with Fisher's exact test. All analyses were two-tailed, and P , 0.05 was considered to be statistically significant. Group data are presented as mean + SEM.
Results
Na 1 -current changes
There was no evidence of changes in cell morphology with DKPQ, and the mean cell capacitances were similar in both groups: WT (84.1 + 5.3 pF; n ¼ 25/5, cells/hearts) vs. DKPQ (80.0 + 3.1 pF; n ¼ 39/8). Figure 1A shows averaged TTX-sensitive I Na recordings based on electronic averages of all recordings obtained from WT and DKPQ cardiomyocytes. Peak currents and overall morphologies are similar. Figure 1B shows averaged currents during the full 200 ms depolarizing pulse on an expanded current scale, illustrating the larger I NaL in DKPQ. I NaL was defined for each cell as the mean TTX-sensitive current between 150 and 200 ms following depolarization. The mean I NaP and I NaL data are shown in Figure 1C and D. DKPQ had no effect on peak currents but increased late-current density about three-fold. Figure 2A shows the average superimposed APs from DKPQ and WT hearts recorded at different frequencies. Because we used an isolated LA preparation that exhibited very little spontaneous automaticity, we were able to record APs over a wide range of frequencies. Figure 2B shows the overall mean + SEM APD 90 results. DKPQ atria had significantly longer APDs over the full range of frequencies tested, with the largest increases seen at slower rates. EADs occurred frequently in DKPQ atria under bradycardic conditions ( Figure 3 ). Figure 3 shows typical single ( Figure 3A ) and multiple ( Figure 3B ) EADs. EADs developed in 10 of 18 (56%) LA DKPQ preparations at 0.5 Hz, but only one of 10 (10%) WT preparations (P , 0.05; Figure 3C ). EADs were rarer at 1 Hz and never observed at higher frequencies (Supplementary material online, Figure S3 ). Figure 4A shows a preparation from a DKPQ mouse in which simultaneous recordings were obtained with two microelectrodes at the locations shown. Recordings during extrasystolic activity are shown in Figure 4B . Cell 1 clearly showed a gradual transition from a prolonged plateau to an EAD, whereas cell 2 showed the upstroke of an extrasystolic AP occurring with a clear but short delay after the EAD upstroke in cell 1. Such activity was seen typically in DKPQ hearts and suggests EAD-induced triggered activity. The upstroke amplitude of the triggered AP depended on the degree of repolarization at the time of activation from the EAD, reflecting the voltage dependency of I Na , as illustrated by the four recordings from cell 2 (AP recordings 1 -4) in Figure 4C . Figure 4D shows recurrent EADs and triggered responses in a bigeminal fashion.
AP changes
Effects of ranolazine
To assess the role of I NaL in EADs and triggered activity of DKPQ hearts, we studied the effects of ranolazine, a selective I NaL blocker. 11 The blue and lavender lines in Figure 5 show ranolazine concentration -response curves for ranolazine inhibition of I NaL and I NaP , respectively, in DKPQ cells. Ranolazine-induced current inhibition was significantly greater for I NaL vs. I NaP in DKPQ myocytes for 10 mM (I NaL : 43.5 + 4.2% and I NaP : 10.3 + 3.6% inhibition; P , 0.001) and 100 mM ranolazine (I NaL : 87.1 + 0.9% and I NaP : 33.6 + 3.2% inhibition; P , 0.001). The 50% inhibitory concentration (IC 50 ) was 12.5 mM (95% confidence limits 9.9 -15.4 mM) for I NaL vs. 151.8 mM (95% confidence limits 113.9-202.3 mM) for I NaP , representing 12-fold greater potency for I NaL . The concentration-response relationship for I NaP inhibition in WT cells, IC 50 121.2 mM (95% confidence limits 81.1 -181.3 mM), was similar to that for DKPQ. The I NaL inhibitory potency could not be tested accurately in WT cells because of the very small size of the current. Figure 6 shows the I Na inhibitory effects of ranolazine at the concentration selected for assessment of effects on APs, 10 mM. Figure 6A and B illustrates the effects on peak and late currents, respectively, in one cell. Overall, 10 mM ranolazine reduced the mean I NaP by 10.3% ( Figure 6C ), whereas the mean I NaL was decreased by 43.5% ( Figure 6D) . The difference in I NaL between WT and DKPQ cells was substantially reduced by ranolazine, with DKPQ cells having a value 126% greater than WT in the absence of the drug vs. 29% larger than WT in the presence of 10 mM ranolazine.
The effect of ranolazine was assessed in parallel experiments with both WT and DKPQ preparations, in which the drug (10 mM) was administered in the bath solution over the same time course as parallel drug-free experiments. In the presence of the drug, the AP shape of DKPQ cells was more similar to that of WT cell APs than to APs recorded from drug-free DKPQ cells (Figure 2A) . Ranolazine produced much smaller effects in WT cells (statistically non-significant; Figure 2B ) than in DKPQ cells, reflecting the relatively small amplitude . EAD results at all frequencies are shown in Supplementary material online, Figure S3 .
of the target current (I NaL ) in WT cells. APD 90 was significantly shorter in DKPQ cells superfused with 10 mM ranolazine than in drugfree DKPQ cells, with the largest changes observed at the slowest stimulation frequencies ( Figure 2B) . Consistent with the notion that EADs and triggered activity in DKPQ atria are due to enhanced I NaL , ranolazine suppressed EADs and triggered activity in DKPQ hearts ( Figure 3 ; P , 0.05). As previously noted with TTX effects on quinidine-induced EADs and in contrast to L-type Ca 2+ -channel blocker effects, 12 ranolazine suppressed EADs by reducing APD to values at which EADs did not occur (in either WT cells or DKPQ cells at faster frequencies), suggesting that EADs were suppressed by reversing APD prolongation that allows EAD formation rather than by suppressing the depolarizing mechanism underlying the EAD itself.
Discussion
In this study, we characterized the LA cellular phenotype of a murine model of LQTS3. The mutation increased I NaL and prolonged APD, with the greatest prolongation evident at low frequencies. APD prolongation at low rates was associated with a propensity for EADs. The response to ranolazine at a concentration highly selective for I NaL inhibition confirmed the role of enhanced I NaL in repolarization delay and arrhythmogenesis. This study demonstrates that atrial APD prolongation secondary to increased I NaL caused by impaired I Na inactivation gate function is sufficient to provoke EADs, and suggests that ranolazine may be a valid therapeutic intervention to prevent atrial arrhythmias in this setting.
Atrial repolarization delay, EADs, and AF
The atrial AP typically has a much shorter plateau and more gradual phase 3 repolarization than ventricular AP, 13 (I NaP and I NaL ) and in WT (I NaP only) mice (n ¼ 3 -6/point) is expressed as normalized block ¼ (I NaBL -I NaR )/I NaBL , where I NaBL and I NaR are currents at pre-drug baseline and in the presence of ranolazine, respectively. Currents were measured with the voltage protocol shown in Figure 1 at steady state during pulsing. Mean data were fitted with the following equation: I C ¼ 1/(1 + 10^((log 10 (IC 50 ) 2 log 10 (C)) × h), where I C is percentage inhibition at concentration C and h is the Hill coefficient. The IC 50 for I NaP (151.8 mM, h ¼ 1.08) is 12 times the value for I NaL (12.5 mM, h ¼ 0.81) in DKPQ cells. Significantly different inhibition was measured for 10 mM (I NaL : 43.5 + 4.2% and I NaP : 10.3 + 3.6%) and 100 mM ranolazine (I NaL : 87.1 + 0.9% and I NaP : 33.6 + 3.2% inhibition; ***P , 0.001; unpaired Student's t-tests). In WT cells, the IC 50 for I NaP was 121 mM (h ¼ 0.81), not substantially different from the values in DKPQ. The I NaL concentration-response to ranolazine could not be accurately determined in WT cells because of the very small size of the current.
demonstrated in guinea pig atrial cardiomyocytes exposed to the I Na inactivation inhibiting toxin, ATX-II. 19 Studies of atrial arrhythmogenesis in engineered models of LQTS have been limited to date, and no cellular work has been reported in the literature. Recent studies in DKPQ mouse hearts suggest that pacing protocols that allowed for transient pauses provoke atrial arrhythmias. 9 An important limitation of these studies in isolated perfused hearts is the restricted range of rates that can be studied because of rapid intrinsic automaticity from the mouse sinoatrial node. In the Blana et al. study of DKPQ hearts, a slight but statistically significant rate-dependent monophasic APD prolongation, reversible by Na + -channel block with flecainide, was documented. 9 In the present study, we were able to investigate systematically a wide range of frequencies because of the very low spontaneous firing rate of isolated mouse LA preparations. This allowed us to demonstrate marked APD prolongation and frequent occurrence of EADs at slow atrial rates.
Underlying mechanisms
Enhanced I NaL was likely the factor leading to atrial EADs and triggered activity in our DKPQ mice. We directly demonstrated enhanced I Na in DKPQ atrial cardiomyocytes, and administration of ranolazine at concentrations we showed to be highly selective for I NaL reversed both APD prolongation and EAD susceptibility. It is known that I NaL is rate-dependent, being enhanced at slow rates. 20 The rate dependence of I NaL likely accounts for the bradycardia dependence of left atrial APD prolongation in DKPQ mice.
The properties of arrhythmogenesis we saw in the present study are very similar to those previously described in ventricular tissue from DKPQ hearts. 5 Ventricular cardiomyocytes showed frequencydependent APD prolongation and EADs similar to what we saw in atrial tissue. Unlike our findings, EADs at the ventricular level also occur upon sudden rate acceleration, possibly reflecting atrial -ventricular differences in plateau ionic currents.
Ranolazine and EAD suppression
Ranolazine was effective in suppressing spontaneous EADs and triggered activity in DKPQ atrial cardiomyocytes. In our DKPQ atrial myocytes, we noted a 12-fold difference in the IC 50 of I NaL vs. I NaP (IC 50 : 12.5 mM for I NaL and 151.8 mM for I NaP ). A similar study on ventricular cardiomyocytes of LQTS3 mice revealed a nine-fold selectivity for I NaL . 11 This relatively small discrepancy may be due to differences in the molecular basis of atrial vs. ventricular Na + -channels. 21 The selectivity of ranolazine for I NaL vs. I NaP is greater than that of a variety of other Na + -channel blockers like mexiletine, with an IC 50 of 2.1 mM for I NaL and 6.5 mM for I NaP , 22 lidocaine (89 and 205-516 mM, respectively) 23, 24 and flecainide (19 and 48 -80 mM).
24,25
The results of the present study indicate that ranolazine may be particularly relevant for the treatment of AF in patients with LQT3 physiology and suggest that it may be potentially useful in other clinical situations in which atrial APD prolongation is a suspected cause of AF.
Novelty and potential significance
These findings constitute to our knowledge the first detailed study of the atrial cellular electrophysiological consequences of genetically defined LQTS. The mechanisms underlying AF are known to be complex and the role of specific potential mechanistic contributors remains poorly understood. 26 The development of EADs may be a mechanistic link between the ion-channel impairment induced by the mutation and the clinically evident atrial arrhythmias in LQTS patients. Our findings may also be relevant to acquired forms of AF associated with an increased I NaL , such as AF occurring in congestive heart failure. 27 This physiology may be particularly important in atrial cardiomyocytes, in which increased I NaL enhances APD, cellular Ca 2+ content, and diastolic intracellular Ca 2+ levels. 28 Similarly, patchclamp studies in atrial cardiomyocytes from AF patients have shown enhanced I NaL and suppression of both I NaL and atrial arrhythmogenesis by 10 mM ranolazine, suggesting that the pathophysiology described here may contribute to AF initiation in some cases of the more common acquired forms of the arrhythmia. 29 Our data add support to the notion that ranolazine may suppress arrhythmias in AF patients by acting on I NaL and that enhanced I NaL in AF patients may be more than just an epiphenomenon. 30 
Limitations
There are significant differences between human and murine electrophysiology; especially in terms of the different contribution of I Kr and I Ks to repolarization. 31 Nevertheless, mouse models have provided important insights into the genetic control of human electrophysiology, and notably in LQT3. 11 Besides its effects on I NaL , ranolazine can also inhibit other ion currents like I Kr and I CaL . 32, 33 We used ranolazine at concentrations that are relatively selective for I NaL ; however, we cannot exclude an antiarrhythmic effect from I NaP inhibition or contributions from effects on other ionic processes. The dose-response data provided do not provide insight into the molecular mechanisms of the ranolazine interaction with its Na + -channel-binding site. Much more detailed studies, including a larger range of concentrations than the 1000-fold range that we assessed, would be needed to evaluate evidence for the number of binding sites and positive or negative cooperativity. Ideally, precise definition of ranolazine interactions with the channel would involve site-directed mutagenesis studies to indicate amino-acid residues needed for binding and X-ray crystallography to determine threedimensional structures that control binding. We saw EADs and marked APD prolongation at pacing rates that are similar to bradycardic rhythms in man, but are very slow for the mouse. The fact that we did not observe marked EADs at high heart rates may explain the observation that spontaneous atrial arrhythmias have only rarely been recorded in this mouse model in vivo.
We attributed the antiarrhythmic effect of ranolazine to effects on I NaL . This explanation is likely because of the much greater effect of ranolazine on I NaL than I NaP and because ranolazine reduced APD in DKPQ mice to values at which EADs were not seen in control mice. However, we did see a statistically significant (albeit small, 10%) decrease in I NaP with 10 mM ranolazine, the concentration used for AP studies, so a contribution of I NaP inhibition to the drug's antiarrhythmic actions cannot be totally excluded.
Since APD prolongation and EAD generation in DKPQ was most prominent at rates under 2 Hz (Figures 2 and 3 ; see Supplementary material online, Figure S2 ), the mechanisms suggested by our results could account for prevention by ranolazine of the triggers for AF initiation (presumably provided by EADs) during sinus rhythm in LQTS patients, but not for arrhythmia termination at the very rapid atrial rates during AF. The efficacy of ranolazine for AF termination 34 must be due to a different mechanism, most likely accumulation of rate-dependent I NaP block typical of fast-unbinding I Na blockers. 35 We adjusted stimulus strength under all conditions to be 50% above excitation threshold. Larger stimulus strengths were required under ranolazine and we cannot exclude an effect of stimulus strength on repolarization.
Conclusions
In atrial cardiomyocytes, a genetically enhanced I NaL prolongs the atrial AP and provokes EADs accompanied by triggered activity at low rates, indicating that atrial cardiomyocytes are capable of manifesting these properties which heretofore have only been reported in ventricular cardiomyocytes from congenital LQTS models. These findings are relevant to the cellular mechanisms of atrial arrhythmia in LQTS patients, identify increased I NaL as a proarrhythmic factor in atrial cardiomyocytes, and suggest that therapies directed at the underlying cellular arrhythmia mechanism are worthy of consideration.
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